Cardiorenal Syndrome Type 1 (CRS-1) is defined as an acute worsening of heart function leading to acute kidney injury and/or dysfunction. It is an important cause of hospitalization which affects the diagnosis as well as the prognosis and treatment of patients. The purpose of this paper is to analyze causes that lead to the development of cardiorenal syndrome type 1 and its clinical consequences, as well as to emphasize the clinical importance of its early detection. The clinical studies and professional papers dealing with etiopathogenesis, diagnosis and treatment of cardiorenal syndrome type 1, have been analyzed. The most important role in the occurrence of cardio renal syndrome type 1 is played by hemodynamic mechanisms, activation of neurohumoral systems, inflammation and imbalance between the production of reactive oxygen species (ROS) and nitric oxide (NO). Diagnosis of cardiorenal syndrome type 1 involves biomarkers of acute renal injury among which the most important are: neutrophil gelatinaseassociated lipocalin (NGAL), cystatin C, kidney injury molecule 1 (KIM-1), liver-type fatty acid binding protein (L-FABP), IL-18 and the values of nitrogen compounds in serum. In addition to a pharmacological therapy, various modalities of extracorporeal ultrafiltration are applied in treatment of CRS-1, particularly if there is resistance to the use of diuretic therapy. As opposed to the experimental models, in clinical practice acute renal injury is often diagnosed late so that the measures taken do not give the expected results and the protective role shown in experimental conditions do not give the same results. For all these reasons, it is necessary to analyze the pathophysiology of renal impairment in cardiorenal syndrome as well as detect early indicators of kidney injury that could have clinical benefit and positive impact on reducing the cost of treatment.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Ronco C McCullough PA Anker SD et al. Acute Dialysis Quality Initiative (ADQI) Consensus Group. Cardiorenal syndromes: an executive summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2010; 165: 54–67.
2. Hata N Yokoyama S Shinada T et al. Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail 2010; 12: 32–7.
3. Ronco C Haapio M House AA Anaveker N Bellomo R. Cardiorenal Syndrome. J Am Coll Cardiol 2008; 52(19): 1527-39.
4. Ronco C House AA Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34(5): 957-62.
5. Ronco C Chionh C-Y Haapio M Anavekar NS House A Bellomo R. The Cardiorenal Syndrome. Blood Purif 2009; 27(1): 114-26.
6. Poskurica M. Cardiorenal syndrome: definition ethyopatogenesis clinical manifestations diagnostic prevention and therapy. In: Acure renal failure: prevention dijagnostic therapy. Poskurica M. Ed : 77-106. Medical faculty Kragujevac Inter print Kragujevac Kragujevac 2009. (in Serbian)
7. Ronco C Haapio M House AA Anavekar N Bellomo R. Cardiorenal Syndrome. In: Cardionephrology 4. Radenković S. Ed.: 13-29. GIP “PUNTA“ Niš 2009.
8. Ronco C McCullough PA Anker SD Anand I Aspromonte N Bagshaw SM et al. Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative(ADQI). In: Cardiorenal Syndromes in Critical Care. Ronco C Bellomo R McCullough PA (eds). Contrib Nephrol. Basel Karger 2010; 165: 54-67.
9. Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Braunwald’s Heart Disease. Libby P Bonow RO Mann Douglas L Zipes DP Braunwald E. (eds). Philadelphia: Saunders Elsevier 2008: 583-610.
10. Petrović D Jagić N Miloradović V Nikolić A Stojimirović B. Cardiorenal syndrome - definition classification and basic principles of therapy. Ser J Exp Clin Res 2010; 11(2): 67-71.
11. Ronco C Cicoira M McCullough P A. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012; 60: 1031–42.
12. Mullens W Abrahams Z Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589–96.
13. Costanzo MR Jessup M. The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol. 2009; 53 (7): 597-9.
14. Kopp UC DiBona GF. Neural regulation of renin secretion. Semin Nephrol 1993; 13: 543–51.
15. Haase M Müller C Damman K Murray PT Kellum JA Ronco C et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: Workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013; 182 : 99–116.
16. Frantz S Ertl G Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444–54.
17. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005; 95: 3C–8C.
18. Mantovani A Garlanda C Bottazzi BP et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006; 45: 326–30.
19. Milo O Cotter G Kaluski E et al. Inflammatory and neurohormonal activation in cardiogenic pulmonary edema: implications on the pathogenesis . and outcome of acute ischemic versus non-ischemic acute heart failure. Am J Cardiol 2003; 92: 222–6.
20. Gullestad L Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005; 95: 17C–23C discussion 38C–40C.
21. Arici M Walls J. End-stage renal disease atherosclerosis and cardiovascularmortality: Is C-reactive protein the missing link? Kidney Int 2001; 59: 407-14.
22. Pastori S Virzì GM Brocca A de Cal M Clementi A Vescovo G et al. Cardiorenal syndrome type 1: a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors. Cardiorenal Med 2015; 5(2): 105–15.
24. Diez C Haneya A Brünger F et al. Minimized extracorporeal circulation cannot prevent acute kidney injury but attenuates early renal dysfunction after coronary bypass grafting. ASAIO J 2009; 55(6): 602–7.
25. McCullough PA Wolyn R Rocher LL Levin RN O’Neill WW. Acute renal failure after coronary intervention: Incidence risk factors and relationship to mortality. Am J Med 1997; 103 : 368 –75.
26. Metra M Nodari S Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. European Journal of Heart Failure 2008; 10(2): 188–95.
27. Cheng H Chen YP. Clinical prediction scores for type 1 cardiorenal syndrome derived and validated in chinese cohorts. Cardiorenal Med 2015; 5(1): 12–9.
28. Forman DE Butler J Wang Y et al: Incidence predictors at admission and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61–7.
29. Mehran R Aymong ED Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393–9.
30. Petrović D. Akutno oštećenje bubrega: etiologija dijagnostika i lečenje. Medicinska Istraživanja 2011; 45(3): 7-13.
31. Aghel A Shrestha K Mullens W Borowski A Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010; 16: 49–54.
32. Pfister R Müller-Ehmsen J Hagemeister J Hellmich M Erdmann E Schneider CA. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure. Intern Med J 2011; 41 (6): 467-72.
33. Petrović D Milovanović D Miloradović V et al. Cardiorenal syndrome type 2: Etiopathogenesis diagnosis and therapy. Med Cas 2012; 46(1): 30–4.
34. Maisel AS Katz N Hillege HL et al. and for the Acute Dialysis Quality Initiative (ADQI) consensus group. Biomarkers in kidney and Heart disease. Nephrol Dial Transplant 2011; 26: 62-74.
35. Shrestha K Borowski AG Troughton RW Thomas JD Klein AL Tang WH. Renal dysfunction is a stronger determinant of system ic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011; 17: 472–8.
36. Campbell CY Clarke W Park H Haq N Barone BB Brotman DJ. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 2009; 104: 389–92.
37. Taglieri N Fernandez-Berges DJ Koenig W et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010; 209: 300-5.
38. Ismail Y Kasmikha Z Green HL McCullough PA. Cardiorenal syndrome type 1: epidemiology pathophysiology and treatment. Semin Nephrol Elsevier 2012; 32(1): 18–25.
39. Petrović D Jagić N Miloradović V Nikolić A Poskurica M Stojimirović B. Kardio-renalni sindrom u akutnoj dekompenzaciji hronične kongestivne srčane slabosti. U: Kardionefrologija 5. Radenković S ed. Nis: GIP PUNTA 2011: 117-26.
40. Felker GM Lee KL Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797–805.
41. Ismail Y Kasmikha Z Green HL McCullough PA. Cardio-renal syndrome type 1: epidemiology pathophysiology and treatment. Semin Nephrol. Elsevier 2012; 32 (1): 18–25.
42. Remuzzi G Perico N Macia M Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 68 (99): S57–65.
43. Sarraf M Masoumi A Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4: 2013-26.
44. Dittrich HC Gupta DK Hack TC Dowling T Callahan J Thomson S. The Effect of KW-3902 an Adenosine A1 Receptor Antagonist on Renal Function and Renal Plasma Flow in Ambulatory Patients With Heart Failure and Renal Impairment. J Card Fail 2007; 13(8): 609–17.
45. Weatherley BD Cotter G Dittrich HC et al. Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. J Card Fail Elsevier Inc 2010; 16(1): 25–35.
46. Konstam MA Gheorghiade M Burnett JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. American Medical Association 2007; 297(12): 1319–31.
47. Udelson JE Smith WB Hendrix GH et al. Acute Hemodynamic Effects of Conivaptan a Dual V1A and V2 Vasopressin Receptor Antagonist in Patients With Advanced Heart Failure. Circulation 2001; 104(20): 2417–23.
48. Srdjan L Dejan P. Prevention of acute renal injury in intensive care units. Med Cas 2012; 46(2): 100–4.
49. O’Connor CM Starling RC Hernandez F et al. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. N Engl J Med 2011; 365(1): 32–43.
50. Lüss H Mitrovic V Seferovic PM et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J. Elsevier 2008; 155(6): 1012.e1–8.
51. Dahle TG Sobotka PA Boyle AJ. A practical guide for ultrafiltration in acute decompensated heart failure. Congst Heart Failure 2008; 14: 83-8.
52. Bart BA. Congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail 2009; 2: 499-504.
53. Udani SM Murray PT. The use of renal replacement therapy in acute decompensated heart failure. Semin Dial 2009; 22: 173-9.
54. Costanzo MA Guglin ME Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-83.
55. Rogers HL Marshall J Bock J et al. A randomized controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. Elsevier 2008; 14(1): 1–5.
56. Bart BA Goldsmith SR Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367(24): 2296–304.
57. Prins KW Wille KM Tallaj JA Tolwani AJ. Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1. Clin Kidney J 2015; 8(1): 87–92.
58. Patarroyo M Wehbe E Hanna M et al. Cardiorenal Outcomes After Slow Continuous Ultrafiltration Therapy in Refractory Patients With Advanced Decompensated Heart Failure. J Am Coll Cardiol 2012; 60(19): 1906–12.
59. Nohria A Hasselblad C Stebbins A et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268–74.
60. Núñez J González M Miñana G et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail. 2012; 14(5): 540-8.
61. Kunin M Arad M Dinour D Freimark D Holtzman E.J. Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: Potential Prognostic Factors. Blood Purif 2013; 35: 285-94.
62. Daniela Marina BB Cassiana G André B. Peritoneal Dialysis in Acute Kidney Injury: Trends in the Outcome across Time Periods. PLoS One. 2015; 10(5): e0126436.